Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie  with an integrated analysis of the ‘burden of therapy’ method

Targeting the epidermal growth factor receptor  pathway remains controversial in pancreatic cancer. Afatinib is an oral irreversible ErbB family blocker approved in non–small-cell lung cancer. This open-label, multicenter, randomised phase II trial evaluated gemcitabine plus afatinib (Gem/afatinib) versus gemcitabine (Gem) alone as first-line treatment for metastatic pancreatic cancer.

Source: European Journal of Cancer - February 12, 2021 Category: Cancer & Oncology Authors: M. Haas, D.T. Waldschmidt, M. Stahl, A. Reinacher-Schick, J. Freiberg-Richter, L. Fischer von Weikersthal, F. Kaiser, S. Kanzler, N. Frickhofen, T. Seufferlein, T. Dechow, R. Mahlberg, P. Malfertheiner, G. Illerhaus, S. Kubicka, A. Abdul-Ahad, R. Snijder, Tags: Original Research Source Type: research